Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP

RESEARCH TRIANGLE PARK, N.C. (April 23, 2009) -- Talecris Biotherapeutics, Inc. today announced the publication of the health-related quality of life results from the largest clinical trial ever conducted in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the April 14, 2009 issue of Neurology.

Read the whole article on Science Blog

More from Science Blog